In a major breakthrough for Pakistan’s pharmaceutical industry, Citi Pharma Limited (CPHL) has successfully completed its first-ever export to the Middle East and North Africa (MENA) region. This milestone signals the company’s growing presence in global markets and reinforces its commitment to delivering high-quality pharmaceutical products internationally.

A New Chapter in Citi Pharma’s Global Growth

Citi Pharma’s inaugural shipment to the MENA region is a testament to its robust international strategy. The export, valued at €560,000, was made possible after the company secured FDA accreditation in September 2024, significantly boosting its credibility on the global stage. The deal was structured with an advance payment of €200,000, while the remaining €360,000 was received upon delivery completion.

Strategic Expansion and Future Plans

With this successful transaction, Citi Pharma aims to establish a strong foothold in MENA, setting ambitious targets for annual exports ranging between €8 million and €10 million. This expansion aligns with the company’s long-term vision of increasing Pakistan’s pharmaceutical exports and strengthening international collaborations.

Impact on Pakistan’s Pharma Industry

This milestone not only enhances Citi Pharma’s global reputation but also serves as a positive indicator for Pakistan’s pharmaceutical sector, showcasing its ability to meet international standards and compete in global markets. The company is now exploring further opportunities in regions such as North America and Europe, ensuring sustainable growth and international recognition.

With its commitment to innovation, quality, and compliance, Citi Pharma is well-positioned to become a key player in the global pharmaceutical industry.